Literature DB >> 24897279

Cost-effectiveness of genotyping to guide treatment.

Michael J Sorich1, Michael D Wiese, Brita Pekarsky.   

Abstract

Keywords:  clinical translation; clinical utility; cost–effectiveness; evidence; pharmacogenetics; pharmacogenomics; prioritization; xxx

Mesh：

Year:  2014        PMID： 24897279     DOI： 10.2217/pgs.14.24

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  2 in total

Review 1.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

2.  Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML.

Authors:  Neil T Mason; Gillian C Bell; Rod E Quilitz; John N Greene; Howard L McLeod
Journal:  J Antimicrob Chemother       Date:  2015-08-01       Impact factor: 5.790
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.